Macaque models for AIDS vaccine development

Current Opinion in Immunology

Volumn 8, Issue 4, 1996, Pages 554-560

  Johnson, R Paul ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY PRODUCTION; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; INFECTION CONTROL; MACACA; NONHUMAN; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINE PRODUCTION;

EID: 0030219920     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80046-X     Document Type: Article

References (42)

1. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, Hunt RD, Kanki PJ, Essex M, Desrosiers RC. Isolation of T-cell tropic HTLV-III like retrovirus from macaques. Science. 228:1985;1201-1204.
2. Letvin NL, Daniel MD, Sehgal PK, Desrosiers RC, Hunt RD, Waldron LM, MacKey JJ, Schmidt DK, Chalifoux LV, King NW. Induction of AIDS-like diseases in macaque monkeys with T-cell tropic retrovirus STLV-III. Science. 230:1985;71-73.
3. Mansfield KG, Lerche NW, Gardner MB, Lackner AA. Origins of simlan immunodeficiency virus infection in macaques at the New England Regional Primate Research Center. J Med Primatol. 24:1995;116-122.
4. Kindt TJ, Hirsch VM, Johnson PR, Sawasdikosol S. Animal models for acquired immunodeficiency syndrome. Adv Immunol. 52:1992;425-475.
5. Hu S-L, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp120. Science. 255:1992;456-459.
6. Daniel MD, Mazzara GP, Simon MA, Sehgal PK, Kodama T, Panicali DL, Desrosiers RC. High-titer immune responses elicited by recombinant vaccinis virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retroviruses. 10:1994;839-851.
7. Stott EJ. Anti-cell antibody in macaques. Nature. 1991;353-393.
8. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the net gene. Science. 258:1992;1938-1941.
9. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. of special interest Lancet. 345:1995;1342-1344 Confirmation that vaccination with an attenuated SIV strain deficient in nef can protect againts cell-free and cell-associated viral challenge.
10. + T cell depletion, anemia and thrombocytopenia.
11. Kestler HW III, Ringler NW, Mori K, Panicali DL, Sehal PK, Daniel MD, Desrosiers RC. Importance of the nef gene for maintenance of high virus loads and development of AIDS. Cell. 65:1991;651-662.
12. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. of outstanding interest J Virol. 70:1996;3724-3733 Results of a vaccine trial examining the ability of the attenuated viruses SIVmac316Δnef and SIVmac239Δ3 to protect against challenge with a virulent SIVmac251 virus at different times following vaccination. Protection was strongly correlated with neutralizing antibodies against primary but not T cell adapted SIV strains; full protection induced by SIVmac239Δ3 did not arise until 79 weeks after infection; and protection against persistent infection did occur in the absence of sterilizing immunity.
13. Clements JE, Montelaro RC, Zink MC, Amedee AM, Miller S, Trichel AM, Jagerski B, Hauer D, Martin LN, Bohm RP, et al. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. of special interest J Virol. 69:1995;2737-2744 Macaques vaccinated with an attenuated macrophage-tropic strain of SIV were protected from infection with a divergent pathogenic strain. Protection in passive transfer experiments correlated with the appearance of cross-neutralizing, relatively high avidity antibodies.
14. Lohman BL, McChesney MB, Miller CJ, McGowan E, Joye SM, VanRompay KKA, Reay E, Antipa L, Pedersen NC, Marthas ML. A Partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol. 68:1994;7021-7029.
15. Marthas ML, Sutjipto S, Higgins J, Lohman B, Torten J, Luciw PA, Marx PA, Pedersen NC. Immunization with a live attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol. 64:1990;3694-3700.
16. Dittmer U, Nisslein T, Bodemer W, Petry H, Sauermann U, Stahl HC, Hunsmann G. Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology. 212:1995;392-397.
17. Reimann KA, Tenner-Racz K, Racz P, Montefiori DC, Yasutomi Y, Lin W, Ransil BJ, Letvin NL. Immunopathogenic events in acute infection of rhesus macaque with simian immunodeficiency virus of macaques. J Virol. 68:1994;2362-2370.
18. Stott EJ, Almond N, Kent K, West W, Wood W, Cranage M, Clarke B, Rud E. Some enigmas of the protection against SIV induced by immunization with cellular antigens or attenuated viruses [abstract]. Reston, VA Seventh Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS. 1994 November;108.
19. + nef-specific cytotoxic T cells in vaccinated macaques. of outstanding interest Nat Med. 1:1995;1167-1173 Nef-specific CTL responses induced by a recombinant vaccinia virus were inversely correlated with the peak of SIV replication after challenge.
20. Heeney JL, Van Els C, De Vries P, Ten Haaft P, Otting N, Koornstra W, Boes J, Dubbes R, Niphuis H, Dings M, et al. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. J Exp Med. 180:1994;769-774.
21. + CTLs and neutralizing antibody responses in rhesus macaques. However, neutralizing antibody response declined relatively rapidly after vaccination and no animals were protected from challenge.
22. Yasutomi Y, Koenig S, Woods RM, Madsen J, Wassef NM, Alving CR, Klein HJ, Nolan TE, Boots LJ, Kessler JA, Letvin NL. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous cell-free simian immunodeficiency virus challenge. of special interest J Virol. 69:1995;2279-2284 Animals with a vaccine-induced CTL response to SIV Gag were not protected against challenge, despite levels of CTLs that appeared similar to those of SIV-infected animals.
23. Hulskotte EG, Geretti AM, Siebelink KH, Van AG, Cranage MP, Rud EW, Norley SG, De VP, Osterhaus AD. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). of special interest J Virol. 69:1995;6289-6296 Vaccination with SIV antigens complexed with immunity-stimulating complexes resulted in both CTL responses and neutralizing antibodies but failed to protect against challenge or to reduce virus load post-challenge.
24. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 355:1992;728-730.
25. Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G, Norrby E. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature. 352:1991;436-438.
26. Gardner M, Rosenthal A, Jennings M, Yee J, Antipa L, Robinson EJ. Passive immunization of rhesus macaques against SIV infection and disease. of special interest AIDS Res Hum Retroviruses. 11:1995;843-854 Passive transfer of serum from an animal immunized with whole, inactivated SIV grown in human cells was able to protect against infection with SIV grown in human but not rhesus cells. Serum from a SIV-infected animal with high titers of neutralizing activity did not protect recipients from infection.
27. Kent KA, Kitchin P, Mills KHG, Page M, Taffs F, Corcoran T, Silvera P, Flanagan B, Powell C, Rose J, et al. Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251. AIDS Res Hum Retroviruses. 10:1994;189-194.
28. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis. 173:1996;340-348.
29. + T-cell levels. AIDS. 7:1993;1159-1166.
30. Israel ZR, Edmonson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, Opstal OV, Bruck C, Bex F, et al. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol. 68:1994;1843-1853.
31. Hirsch VM, Goldstein S, Hynes NA, Elkins WR, London WT, Zack PM, Montefiori D, Johnson PR. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis. 179:1994;51-59.
32. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Platak MJ, Elkins WR, Alvord WG, Montefiori DC, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus ankara. of special interest J Virol. 70:1996;3741-3752 High levels of SIV replication following challenge predict rapid progression to AIDS; low levels of viremia correlate with delayed clinical progression.
33. Haigwood NL, Watson A, Sutton W, McClure J, Lewis J, Ranchalis J, Travis B, Voss G, Letvin N, Hu S-L, et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. of outstanding interest Immunol Lett. 1996; Passive transfer of immunoglobulin from a healthy SIV-infected monkey to acutely infected macaques resulted in decreased viral load and delayed progression to AIDS.
34. Mellors JW, Rinalso CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
35. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
36. Yasutomi Y, Robinson HL, Lu S, Mustafa F, Lekutis C, Arthos J, Mullins JI, Voss G, Manson K, Wyand M, Letvin NL. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol. 70:1996;678-681.
37. Arthur LO, Bess JJ, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, Benveniste RE. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. of special interest J Virol. 69:1995;3117-3124 Immunization with HLA-DR protected animals from infection from SIV propagated in human but not rhesus cells.
38. Chen ZW, Kou ZC, Lekutis C, Shen L, Zhou D, Halloran M, Li J, Sodroski J, Lee PD, Letvin NL. T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J Exp Med. 182:1995;21-31.
39. Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J AIDS. 5:1992;639-646.
40. Luciw PA, Pratt LE, Shaw KE, Levy JA, Cheng MC. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci USA. 92:1995;7490-7494.
41. Igarashi T, Shibata R, Hasebe F, Ami Y, Shinohara K, Komatsu T, Stahl-Hennig C, Petry H, Hunsmann G, Kuwata T, et al. Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys. AIDS Res Human Retroviruses. 10:1994;1021-1029.
42. + T-cell depletion in several weeks, subsequently accompanied by clinical symptoms of AIDS.